Novo Nordisk Rises as Q3 Wegovy Pill Sales, Profit Beat Forecasts

By Dominic ChoppingNovo Nordisk raised its guidance for the year after noting an improved outlook for its key obesity and diabetes drugs, particularly in markets outside the U.S., as it continues the rollout of its new weight-loss pill.Shares climbed 4.5% on the news.The Danish drugmaker said Wedne…